Effect of silymarin in the treatment of patients with depressio

Phase 3

Not yet recruiting

• Conditions: Depression.; Major depressive disorder, single episode, moderate; F32.1

• Registration Number: IRCT20160804029191N4
• Lead Sponsor: Mashhad University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 11 January 2022

Recruitment & Eligibility

• Status: Pending
• Sex: All
• Target Recruitment: 80

Inclusion Criteria

Patients with moderate depression
Being 20-50 years old
Patient consent to participate in the study
Not having specific physical (e.g. cancer, Acquired immunodeficiency syndrome (AIDS), Multiple Sclerosis (MS)) or mental illness
Not having allergic to silymarin
Not being pregnant/breast feeding

Exclusion Criteria

Lack of patient cooperation in silymarin consumption
Having allergic reaction or intolerable side effect caused by silymarin

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Beck Depression Inventory (BDI) questionnaire. Timepoint: Before treatment (day 0) and at the end of weeks 4 and 8 after starting treatment. Method of measurement: Completion of the questionnaire by patient or researcher.;General Health Questionnaire (GHQ). Timepoint: Before treatment (day 0) and at the end of weeks 4 and 8 after starting treatment. Method of measurement: Completion of the questionnaire by patient or researcher.